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Infections caused by methicillin-sensitive Staphylococcus aureus (MSSA) and
methicillin-resistant S. aureus (MRSA) are prevalent. MRSA infections are difficult to
treat and there are no new classes of antibiotics produced to the market to treat
infections caused by the resistant bacteria. Therefore, using antibiotic enhancers to
rescue existing classes of antibiotics is an attractive strategy. Nordihydroguaiaretic acid
(NDGA) is an antioxidant compound found in extracts from plant Larrea Tridentata.
It exhibits antimicrobial activity and may target bacterial cell membrane. Combination
efficacies of NDGA with many classes of antibiotics were examined by chequerboard
method against 200 clinical isolates of MRSA and MSSA. NDGA in combination
with gentamicin, neomycin, and tobramycin was examined by time-kill assays. The
synergistic combinations of NDGA and aminoglycosides were tested in vivo using a
murine skin infection model. Calculations of the fractional inhibitory concentration index
(FICI) showed that NDGA when combined with gentamicin, neomycin, or tobramycin
displayed synergistic activities in more than 97% of MSSA and MRSA, respectively.
Time kill analysis demonstrated that NDGA significantly augmented the activities of these
aminoglycosides against MRSA and MSSA in vitro and in murine skin infection model.
The enhanced activity of NDGA resides on its ability to damage bacterial cell membrane
leading to accumulation of the antibiotics inside bacterial cells. We demonstrated that
NDGA strongly revived the therapeutic potencies of aminoglycosides in vitro and in vivo.
This combinational strategy could contribute major clinical implications to treat antibiotic
resistant bacterial infections.
Keywords: nordihydroguaiaretic acid, gentamicin, neomycin, tobramycin, Staphylococcus aureus, antibiotic
combination
INTRODUCTION
There is no doubt that antimicrobial discovery and development experienced an era of prosperity
in the not so distant past, known as the “golden era of antibiotics” (Aminov, 2010). However, this
era of prosperity has come to an end due to rapid emergence of antibiotic resistance in bacteria
and a dramatically reduced rate in discovery of new antibiotic classes (Sheridan, 2005). This matter
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is of great concern in the treatment of infections such as
those caused by methicillin-resistant Staphylococcus aureus
(MRSA). Methicillin-sensitive S. aureus (MSSA) and MRSA are
major causes of life-threatening infections including surgical
site infections, bacteraemia, pneumonia and catheter-associated
infections (Fry and Barie, 2011; Magret et al., 2011), leading
to signiﬁcant morbidity and mortality. There is a very
limited antimicrobial armamentarium to treat MRSA infections,
of which vancomycin (a glycopeptide) and linezolid (an
oxazolidinone antibiotic) are the major antibiotics. Worryingly,
some cases of MRSA infections are also resistant to vancomycin
(Liu and Chambers, 2003) and linezolid resistance has recently
emerged (Gu et al., 2013). This combined with a signiﬁcantly
narrowed antibiotic pipeline (Butler et al., 2013) indicates that
our ability to treat MRSA infections is rapidly diminishing
(Lowy, 2003; Sheridan, 2005; Boucher et al., 2009). Therefore,
using antibiotic enhancers (Kalan and Wright, 2011; Hu and
Coates, 2012; Hu et al., 2015) as a means to revive existing
classes of antibiotics provides an attractive strategy to combat
the recent upsurge in antibiotic resistance. Aminoglycosides
are not typically used to treat Gram-positive infections, but
are known to exhibit a degree of anti-staphylococcal activity
(Vakulenko and Mobashery, 2003). The potential that the
anti-staphylococcal activities of aminoglycosides oﬀer makes
them particularly an attractive option. Additionally, revival
of this class in treatment of MRSA would allow reduced
vancomycin usage which ideally should only be used as a last
resort.
Nordihydroguaiaretic acid (NDGA) is an antioxidant
compound (Figure 1) found in extracts from Larrea Tridentata,
a plant of great ethnobotanical importance. This antioxidant has
a wide range of uses including tumor prevention, chemotherapy
and treatment of the herpes simplex virus (Lu et al., 2010).
It has been reported that NDGA showed anti-staphylococcal
activity (Cowan, 1999; Gokbulut et al., 2013; Ooi et al.,
2015), which may be due to the eﬀect of NDGA on bacterial
cell membrane (Ooi et al., 2015). Unfortunately, NDGA
may possess potential adverse systemic eﬀects such as non-
competitive inhibition of sex hormones and nephrotoxicity
(Lambert et al., 2002; Lu et al., 2010) at higher doses; the true
nature of such eﬀects is largely unknown (Lu et al., 2010).
A recent study (Ooi et al., 2015) demonstrated that NDGA
FIGURE 1 | Chemical structure of Nordihydroguaiaretic acid (NDGA).
at low concentrations was able to increase the potency of
gentamicin against S. aureus bioﬁlm and suggested that the
combination of NDGA with gentamicin could potentially be
used to treat superﬁcial staphylococcal infections. As NDGA
might act on bacterial cell membrane (Ooi et al., 2015),
potentially it could be used as an antibiotic enhancer (Hu and
Coates, 2012) to boost the activities of other antibiotic such as
aminoglycosides.
In this study, we retrospectively tested the in vitro and
in vivo activities of NDGA in combination with many classes of
antibiotics, but mainly focused on aminoglycosides using clinical
isolates of MSSA and MRSA.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Bacterial strains used were clinical isolates of MSSA (n = 100)
andMRSA (n = 100) isolated from St George’s Hospital, London.
These isolates were collected from blood cultures, tissue ﬂuid,
or routine screening on skin of the patients in the South West
London area.Most of these strains were isolated from bacteremia.
Some were isolated as organ or skin colonization. Genotyping of
these strains were performed previously (Hu et al., 2015). The
isolates were grown in nutrient broth (Oxoid) or on trypticase
soy agar (Oxoid) plates.
Susceptibility Tests of Antibiotics and
NDGA
The minimum inhibitory concentration (MIC) was determined
in 96-well plates using Iso-Sensitest broth (Oxoid) in accordance
with the Clinical and Laboratory Standards Institute guidelines
for broth microdilution MIC (Barry, 1999). Serial twofold
dilutions of antibiotics were prepared in triplicate followed
by addition of a standard bacterial suspension of 1–5 × 105
colony forming unit (CFU)/mL. After 24 h incubation at 37◦C,
the optical density (OD) readings were measured using an
ELx800 absorbance microplate reader (BioTek). The MIC was
determined as the lowest concentration of an antibiotic with
similar OD reading as the control (medium only). NDGA (purity
at 97%) and the antibiotics used in the study were obtained from
Sigma–Aldrich UK.
Chequerboard Analysis to Determine
Combination Effect of NDGA with
Antibiotics
The chequerboard assay was used for the measurement of
combination eﬀects of NDGA with antibiotics. Combinations
of two drugs were prepared using 96 well plates with drug
concentrations starting from twofold higher than their MIC
values, then serially diluted in a twofold manner. The two
drugs were mixed in a 96 well plate followed by addition of
a standard bacterial suspension of 1–5 × 105 CFU/mL. After
24 h incubation at 37◦C, the OD readings were determined
using an EL × 800 absorbance microplate reader (BioTek). The
combination eﬀects were determined by calculating the fractional
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inhibitory concentration index (FICI) as follows: (MIC of drug
A, tested in combination)/(MIC of drug A, tested alone) + (MIC
of drug B, tested in combination)/(MIC of drug B, tested alone).
The eﬀects of the combination were deﬁned as synergy if the
FICI was ≤0.5, no interaction if the FICI was >0.5 but ≤4.0 and
antagonism if the FICI was>4.0 (Odds, 2003).
Time Kill Analysis of Aminoglycoside
Combinations with NDGA against MSSA
and MRSA
A range of diﬀerent concentrations of NDGA and antibiotics
singly or in combination were incubated with bacterial cultures
containing 107 CFU/mL of the test isolates. At 0, 1, 2, 4, 7,
and 24 h of incubation, viability was determined by plating
100µL of serial dilutions onto trypticase soya agar plates followed
by incubation at 37◦C for 24 h. The CFU was counted using
aCOLyte colony counter (Synbiosis) and analyzed using the
counter’s software. Viability was expressed at log CFU/mL.
Measurement of ATP Release
The eﬀect of NDGA on bacterial cytoplasmic membrane
damage was measured by leakage of ATP according to the
methods described previously (Johnston et al., 2003; Oliva et al.,
2004; Ooi et al., 2009) using the CellTiter-Glo luminescent
cell viability kit (Promega). S. aureus clinical strains were
treated with diﬀerent concentrations of NDGA and control
antimicrobial agents for various time periods. Negative controls
were included as CellTiter-Glo reagent with buﬀer and
CellTiter-Glo reagent with bacterial cells without drug. The
luminescence was measured using GloMax-Multi+ microplate
reader (Promega).
Mouse Superficial Skin Infection Model
The mouse superﬁcial skin infection model was performed as
described previously (Kugelberg et al., 2005; Hu and Coates,
2012) using female ICR mice (6–8 weeks old, Charles River). The
mice were anesthetized by intraperitoneal injection of 200 µL
of a 1:1:2 mixture of 100 mg/mL ketamine hydrochloride,
20 mg/mL xylazine, and sterile water. An area of 2 cm2 skin
was tape-stripped using an autoclave tape after removal of the
fur on the mouse back. The skin was stripped 10 times in
succession. This procedure damaged the skin by removing the
top dermal layers, which became red and shiny, but without
observable bleeding. Buprenorphine was given at 0.2 mg/kg
body weight during the anesthetic period and every 12 h to
reduce pain. Bacterial infection was induced by the addition of
25 µL of log phase culture containing 107 bacterial cells on
the stripped skin. At 24 h after infection, treatment with the
antibiotic formulation was initiated. At diﬀerent time points
after infection and treatment, three mice were sacriﬁced by
cervical dislocation. The skin, approximately 2 cm2 was cut
and added to 2 mL tubes which contained 1 mL water
and glass beads (1 mm). The skin was homogenized using
a SpeedMill PlusTM (AnalytikJena) homogenizer for 1 min.
Antibiotic remaining on the skin was removed by washing three
times with water. CFU counts were performed on serial dilutions
of the homogenates.
All animal experiments were performed according to the
Animals Scientiﬁc Procedures Act, 1986 (anAct of the Parliament
of the United Kingdom 1986 c. 14; Home Oﬃce Project licence
Number 70/7077) with approval from St George’s, University of
London ethics committee.
Statistical Analysis
The signiﬁcance of diﬀerences between experimental groups was





The activities of antibiotics such as amoxicillin, penicillin,
gentamicin, neomycin, tobramycin, clarithromycin, and
erythromycin in combination with NDGA were determined
using the chequerboard method against the 100 MSSA and
100 MRSA isolates. Synergistic activities were only observed
when NDGA was combined with gentamicin, neomycin, and
tobramycin for both MSSA and MRSA. As seen in Table 1,
MICs for gentamicin, neomycin, and tobramycin for MSSA
ranges from 0.125 to 1 mg/L, 0.5 to 1 mg/L, and 0.125 to
1 mg/L, respectively, showing all strains being susceptible to the
aminoglycosides (break point for gentamicin and tobramycin
is 1 mg/L; EUCAST, 2013). However, for the MRSA strains,
although 50% of the strains were susceptible, some strains were
highly resistant to the three antibiotics. There are 18 gentamicin
resistant, 25 neomycin resistant, and 27 tobramycin resistant
MRSA (Supplementary Data Sheet S1). NDGA showed high
MIC value against both MSSA and MRSA (Table 1).
TABLE 1 | Minimal inhibitory concentration (MIC) of gentamicin, neomycin,
tobramycin, and Nordihydroguaiaretic acid (NDGA) against clinical
isolates of methicillin-sensitive Staphylococcus aureus (MSSA) and
methicillin-resistant S. aureus (MRSA).
MICa (mg/L)
Bacterial strains Agentsb MIC range MIC50 MIC90
MSSAc Gentamicin 0.125–1 0.25 0.5
Neomycin 0.5–1 0.5 1
Tobramycin 0.125–1 0.25 0.5
NDGA 16–128 32 32
MRSAd Gentamicin 0.03–512 0.125 16
Neomycin 0.06–512 0.5 32
Tobramycin 0.03–512 0.125 64
NDGA 8–64 32 64
aMIC50 and MIC90 50% and 90% indicate that MIC values at which 50 and
90% of the isolates were inhibited, respectively. bBreak point for gentamicin and
tobramycin is 1 mg/L (EUCAST, 2013). Break point for neomycin and NDGA are
not available. cn = 100; dn = 100.
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TABLE 2 | Combination activities of NDGA with gentamicin, neomycin, and
tobramycin against MSSA and MRSA.
Total no. (%) of strains detected
when NDGA combined with
Strains Combination
activity
FICI Gentamicin Neomycin Tobramycin
MSSA Synergy <0.5 99(99%) 100 (100%) 100 (100%)
No
interaction
0.56–4 1 (1%) 0 0
Antagonism >4 0 0 0
MRSA Synergy <0.5 98(98%) 100 (100%) 97 (97%)
No
interaction
0.56–4 2 (2%) 0 3 (3%)
Antagonism >4 0 0 0
Combination of gentamicin, neomycin, and tobramycin
with NDGA (Table 2) displayed synergistic interaction against
99, 100, and 100% of MSSA and 98, 100, and 97% of
MRSA isolates, respectively. Additionally, the MICs of all
three aminoglycosides were signiﬁcantly reduced from 2- to
128-fold against MSSA (Supplementary Data Sheet S2) and
2- to 256-fold against MRSA (Supplementary Data Sheet S1)
when used in combination with NDGA, signiﬁcantly, for
the antibiotic resistant MRSA isolates (Supplementary Data
Sheet S1).
Time Kill Analysis of Combinations
against MRSA and MSSA
The synergistic activity of NDGA in combination with
gentamicin, neomycin, and tobramycin was examined in seven
strains of both MRSA and MSSA. The range of concentrations
for each drug was determined according to the results obtained
from chequerboard which displayed an FIC index <0.25. The
combinations with the lowest concentration of NDGA (4 mg/L)
which stimulated the most eﬀective synergistic activity are
shown. Dose dependent eﬀects of NDGA enhancement for
gentamicin, neomycin and tobramycin against MSSA and
MRSA are shown in Supplementary Data Sheet 3. As seen
in Figure 2, NDGA at 4 mg/L showed no eﬀect against both
MSSA and MRSA strains. Gentamicin at a concentration of 0.25
(MSSA) and 0.5 (MRSA) mg/L displayed initial bacterial kill,
but regrowth was seen after 4 h (Figure 2A) of drug exposure
for MSSA and 7 h (Figure 2B) for MRSA. However, gentamicin
and NDGA combination reduced the initial inoculum from 107
CFU/ml to zero at one hour for both strains (Figures 2A,B).
As shown in Figures 2C,D, bactericidal eﬀects of neomycin
at concentrations of 0.25 (MSSA) and 0.5 (MRSA) mg/L
were observed initially but diminished by bacterial regrowth.
However, in combination with 4 mg/L of NDGA, rapid kill
(100% reduction) was seen at 1 h for MSSA and 2 h for MRSA.
Tobramycin at 0.25 mg/L was bactericidal against the MSSA
at 4 h of drug treatment followed by regrowth (Figure 2E)
and 0.5 mg/L inhibited the MRSA growth (Figure 2F). In
combination with NDGA, complete kill was seen at 2 h for
MSSA and 6 h for MRSA. There were no regrowth for the
combination of NDGA with all three aminoglycosides at 24 and
48 h of (Data not shown) incubation. The regrowth that occurred
following single drug treatment may be attributable to drug
degradation or as a result of microorganism adaptation (Chan
and Zabransky, 1987; Aeschlimann et al., 1999). The similar
combination proﬁles of NDGA and the aminoglycosides were
conﬁrmed in diﬀerent strains of MSSA and MRSA (Data not
shown).
NDGA Boosted the Effects of
Gentamicin, Neomycin, and Tobramycin
against MRSA and MSSA in Mouse Skin
Infection Model
We investigated whether NDGA would synergise and improve
the therapeutic eﬀects of topical aminoglycoside formulations
currently on the market. Naseptin R©(0.5% neomycin sulfate and
0.1% chlorhexidine hydrochloride, Alliance), Genticin R©(0.3%
gentamicin, Amdipharm), or Tobradex R©(tobramycin 0.3% and
dexamethasone 0.1%, Alcon) alone and in combination with
NDGA (32 mg/L) were tested against one MRSA and one MSSA
on mouse skin. Both test strains were isolated from bacteremia
with a NDGA MIC of 32 mg/L and gentamicin, neomycin,
and tobramycin MIC of 1, 0.5, and 1 mg/L; respectively. These
strains showed FIC indices <0.5 and signiﬁcant synergistic
activities in time kill curve for each of the drug combinations.
After a bacterial infection was established at 24 h after
inoculation, 45 µL of either Genticin R©, Naseptin R©, Tobradex R©,
NDGA, combination of NDGA with the formulations and
placebo were applied to the infected area. Bacterial CFU
counts were then taken after 24 h of treatment. As shown
in Figure 3, NDGA showed no eﬀect as a single agent
(n = 3) whilst Genticin R© , Naseptin R©, and Tobradex R© all have
similar eﬀects (n = 3), causing a reduction of 2.4–2.9 log
in CFU counts against both MSSA (Figure 3A) and MRSA
(Figure 3B). However, the eﬀects of each formulation in
combination with NDGA (n = 3) were signiﬁcantly augmented
(P < 0.001), leading to CFU count reductions of 4.2–4.9 logs
compared to the placebo control in both MSSA and MRSA
infections.
Determining the Effect of NDGA on
Bacterial Cytoplasmic Membrane
Damage
Bacterial membrane damage was examined by ATP leakage
after exposure of the S. aureus strain to NDGA and other
antimicrobial agents. As shown in Figure 4, ciproﬂoxacin and
tetracycline (4× MIC) resulted in no ATP leakage which
was similar to previous ﬁnding (Oliva et al., 2004). The cell
membrane damage agents HT61 (1× MIC) and nisin (4×
MIC) permeabilized the cell membrane leading to leakage
of signiﬁcant amounts of ATP. However, NDGA (4× MIC)
exposure produced amounts of ATP which was more than 40%
of the control value over the period tested indicating that NDGA
was a cytoplasmic membrane damage agent (Hilliard et al.,
1999).
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FIGURE 2 | Time-kill analysis showing the effects of NDGA in combination with gentamicin, neomycin, and tobramycin against log phase
methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA). NDGA and the antibiotics alone or each antibiotic
combined with NDGA were added to the log-phase cultures and colony forming unit (CFU) counts were carried out at different time points. Concentrations of NDGA
was 4 mg/L. The three aminoglycoside concentrations were 0.25 mg/L for MSSA and 0.5 mg/L for MRSA. Combination of NDGA with gentamicin against MSSA (A)
and MRSA (B). Combination of NDGA with neomycin against MRSA (C) and MRSA (D). Combination of NDGA with tobramycin against MSSA (E) and MRSA (F).
Results shown are mean of two independent experiments.
DISCUSSION
In this study, we showed that NDGA boosted the antibacterial
eﬃcacies of aminoglycosides, namely gentamicin, neomycin, and
tobramycin, against MSSA and MRSA both in vitro and in
a mouse infection model. The use of NDGA as an antibiotic
enhancer may contribute to the production of novel therapeutic
topical regimens for the treatment of antibiotic-resistant S. aureus
infections.
Although aminoglycosides are highly eﬀective broad spectrum
antibiotics with anti-staphylococci activities (Vakulenko and
Mobashery, 2003), they exhibit a wide range of clinically
signiﬁcant side-eﬀects. These include nephrotoxicity or
ototoxicity aﬀecting the vestibulo-cochlear system (Selimoglu,
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FIGURE 3 | Effect of NDGA boosting the effects of currently marketed
formulations containing gentamicin, neomycin, and tobramycin
against MSSA and MRSA in a murine skin bacterial infection model.
Viability of the bacteria was determined after 24 h of treatment. Treatment with
NDGA, Genticin, Naseptin, and Tobradex singly or in combination against
MSSA (A) and MRSA (B). The data has been repeated twice. ∗∗∗P < 0.001.
2007). The potential for irreversible nephrotoxicity limits
neomycin to topical or oral administration (Edson and Keys,
1983). Overall, toxic side-eﬀects signiﬁcantly curtail the
therapeutic usage of aminoglycosides in the status quo (Quiros
et al., 2011; Mazurek et al., 2012).
In this study, NDGA alone showed no signiﬁcant anti-
staphylococcal activities against MSSA and MRSA showing
MIC values between 16 and 128 mg/L, which conﬁrmed
previous ﬁndings (Ooi et al., 2015). When NDGA was used
in combination with gentamicin, neomycin, and tobramycin,
signiﬁcant synergistic activity was observed against more than
97% of the test isolates. The synergistic interactions observed
here were conﬁrmed by time-kill assays, which has been
repeatedly shown to be superior to chequerboard analysis (Hu
and Coates, 2012; Hu et al., 2015) as it measures dynamically the
antimicrobial activities of the combination over time. Our time
kill studies showed that gentamicin at 2 to 4 mg/L, neomycin
at 2 to 8 mg/L, and tobramycin 2 to 4 mg/L, led to complete
eradication of log phase MSSA or MRSA within 1 to 4 h
(data not shown). Lower concentrations of 0.25 to 0.5 mg/L
FIGURE 4 | Effect of NDGA and other antimicrobial agents on leakage
of ATP against a clinical isolate of MSSA. The bacterial strain was
resuspended in HEPES buffer supplemented with glucose and treatment with
ciprofloxacin, tetracycline, NDGA, HT61, and nisin. The experiments have
been repeated twice with reproducible results.
of all three aminoglycosides showed initial bactericidal activity
followed by regrowth (Figure 2). Importantly, after addition
of 4 mg/L of NDGA, rapid bactericidal activities (100% kill)
were seen with low doses of the aminoglycosides (Figure 2)
which gave the equivalent potency of the antibiotic used singly
to achieve a complete kill. Furthermore, the culture remained
free of bacteria even after 48 h of incubation (data not shown)
indicating that all the bacteria were eliminated. The enhancement
of aminoglycoside bactericidal activities by NDGA is important
as therapeutic eﬀects can be achieved with lower doses of
aminoglycoside and this dose reduction would signiﬁcantly
reduce the potential for toxic side eﬀects. Aminoglycoside
enhancer has been shown previously (Mitchell et al., 2012) to
increase the drug potency against both antibiotic-susceptible and
antibiotic-resistant S. aureus. Bacterial strains used in this study
were clinical isolates randomly selected from patients with a
range of infections, the majority of which were associated with
bacteraemia (Hu et al., 2015). These isolates were genotypically
diverse and included representatives of the dominant lineages of
S. aureus recovered from humans (Hu et al., 2015). This strongly
supports the notion that NDGA-aminoglycoside combinations
are eﬀective in a genotypically diverse population of S. aureus.
The therapeutic potential of NDGA as an aminoglycoside
enhancer was demonstrated on the treatment of mouse MSSA
and MRSA skin infections. We clearly showed that combinations
of NDGA with current marketed formulations, Genticin
(gentamicin), Naseptin (neomycin), Tobradex (tobramycin),
signiﬁcantly boosted the eﬃcacies of the formulations and
reduced around 2 logs more of the bacterial loads on the skin.
These enhanced eﬀects are particularly important as the fast
action of the combination is likely to shorten the treatment
duration. Since long-term administration of aminoglycosides
render bacteria susceptible to the development of antibiotic
resistance (Buckwold et al., 1979), the potential to shorten
antibiotic therapy duration and still achieve the same degree of
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therapeutic activities can reduce antibiotic resistance emergence
which may improve clinical outcomes (Magana et al., 2015).
Increasing cell permeability is one of the major modes of
action for antibiotic enhancers (Hu and Coates, 2012; Hu et al.,
2015; Magana et al., 2015). Compounds which target the cell
wall or cell membrane have been shown to boost the therapeutic
activities of antibiotics (Giacometti et al., 2000; Anantharaman
et al., 2010; Hu and Coates, 2012; Hu et al., 2015). It is
well established that membrane potential is a major factor
determining the degree of aminoglycoside uptake (Mates et al.,
1982). We showed that NDGA exposure led to bacterial ATP
leakage indicated that NDGA damaged S. aureus cell membrane
which is in agreement with the ﬁnding reported previously (Ooi
et al., 2015). Aminoglycosides inhibit bacterial protein synthesis
and their bactericidal activities are concentration dependent
(Hancock, 1981). Therefore, increased bactericidal activities are
associated with increased bacterial intracellular concentration
of the antibiotics. The eﬀect of the increased membrane
permeability induced by NDGA resulted in accumulation of the
antibiotics inside bacterial cells leading to increased levels of the
antibiotics intracellularly, thus contributed enhanced bacterial
kill. Similar studies showed that cell membrane damage agent
enhanced aminoglycoside activities against S. aureus (Hu and
Coates, 2012).
CONCLUSION
This study showed that NDGA in combination with
aminoglycosides can successfully remove both MSSA and
MRSA in vitro and signiﬁcantly reduced the bacterial burden
in vivo. This combination therapy may allow a lower dose
of aminoglycosides to be used while maintaining therapeutic
potency. The ability of NDGA to rejuvenate the eﬃcacy of
the antibiotics resides in its ability to permeabilize bacterial
cytoplasmic membrane with a potential to allow accumulations of
the combined antibiotics in the target site. Our groundwork has
provided early preclinical assessments of NDGA combination
with aminoglycosides and lays the foundation for further
validation for clinical usage.
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